Antibody Drug Conjugates Market
Number of pages: 100 | Report Format: PDF | Published date: March 07, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 9.45 billion |
|
Revenue Forecast in 2031 |
US$ 24.56 billion |
|
CAGR |
16.5% |
|
Base Year for Estimation |
2021 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Technology, Application, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global antibody drugs conjugates market was valued at US$ 9.45 billion in 2022 and is expected to register a revenue CAGR of 16.5% to reach US$ 24.56 billion by 2031.
Antibody Drug Conjugates Market Fundamentals
Conjugation is the covalent bonding of drugs to natural or synthetic molecular carriers for targeted use, such as polypeptides or proteins, lipids, polymers, and carbohydrates. Conjugation has evolved into an important method for drug release and targeted drug delivery of tiny molecules and biotherapeutic modalities, such as protein-drug conjugation, antibody-drug conjugation, polymer-drug conjugation, and T-cell dual affinity re-targeting conjugation. Drug conjugation can increase pharmacokinetics, medication stability, and pharmacodynamic qualities while also changing toxicity profiles. Antibody-drug conjugate (ADC) is a biopharmaceutical medicine designed to treat and cure cancer. In contrast to chemotherapy, ADCs are utilized to selectively eliminate cancer cells without harming the healthy ones.
The discovery of the specific antigenic target of the monoclonal antibody (mAb) component is one of the most critical parts of ADC development for cancer. For instance, the HER2 receptor is over 100-fold more abundant in tumor cells than in healthy cells. Second, the target antigen must be present on the surface of the tumor cell to the circulating mAb to recognize it. Third, the target antigen should have internalization properties to help the ADC transport into the cell, improving the cytotoxic agent’s efficacy. However, some studies have shown that noninternalized ADC products directed against components of the tumor microenvironment can efficiently detach their drug in the extracellular space and arbitrate a potent therapeutic activity in some cases and that ADCs frequently induce a shunt. The most targeted antigens in ADCs include ERBB2, CD19, CD33, CD22, and MSLN (mesothelin). Furthermore, ADC has used approximately 50 distinct recognized antigens as a target. Previous research has shown that several tumor antigens are also expressed at low levels in normal cells. The antigen MSLN, for instance, which is overexpressed in mesothelioma, ovarian, pancreatic, and lung adenocarcinomas, was shown to be low expressed in healthy cells. Golfier and colleagues created a novel ADC against mesothelin that shows high potency in patient-derived xenograft tumor models. Still, it also had a bystander effect on mesothelin-negative tumor cells.
Linkers are important in ADC design as they connect the cytotoxic drug to the mAb. When the ADC complex moves in the circulation, the linker must be maintained to prevent the deadly drug from being released in off-target tissue, and the linker must keep the conjugate in an inactive, harmless condition while linked to the antibody. Simultaneously, the linker should be capable of releasing the cytotoxic chemical upon internalization. Cleavable linkers and non-cleavable linkers are the two types of linkers.
[5756756]
Antibody Drug Conjugates Market Dynamics
ADCs are one of the most successful cancer treatments. They can use the specificity of monoclonal antibodies towards targeted antigens to release potential cytotoxic medicines with higher activity and lower toxicity than chemotherapies. ADCs are cancer treatments that use antibodies as a vehicle to deliver high-potential cytotoxic drug molecules to specific tumor-related antigens. The growing number of cancer cases worldwide drives revenue growth in the market under consideration. For instance, the Globocan 2020 database reported 19.3 million new cancer cases in 2020. Cancer incidence is anticipated to rise to 21.8 million by 2025 and 28.8 million by 2040. Breast cancer (11.7%) was the most common cancer, followed by lung cancer (11.4%), colorectal cancer (10%), prostate cancer (7.3%), stomach cancer (5.6%), and other cancers (53.9%). As a result of the expanding cancer burden, there is an increased demand for better treatments, which may significantly drive the market throughout the projection period.
According to the Globocan 2020 database, about 50% of cancer patients are 65 and older. By 2040, this figure is predicted to double. As a result, the growing senior population is increasing cancer diagnoses and driving demand for ADCs. For instance, according to a United Nations factsheet from 2022, there will be 771 million individuals aged 65 and up worldwide in 2022. The elderly population is expected to increase to 994 million by 2030 and 1.6 billion by 2050. As a result, the expanding aging population may increase the occurrence of cancer and fuel market expansion.
Technological advancements are propelling the market forward. For instance, in February 2022, ImmunoGen Inc. signed a global, multi-year definitive licensing agreement with Eli Lilly and Company, under which it granted Eli Lilly and Company exclusive rights to research, develop, and commercialize ADCs directed towards targets selected by Lilly based on ImmunoGen’s novel camptothecin technology.
Antibody Drug Conjugates Market Ecosystem
The global antibody drug conjugates market has been analyzed from four perspectives: technology, application, distribution channel, and region.
Antibody Drug Conjugates Market by Technology
[76565464]
Based on technology, the global antibody drug conjugates market has been segmented into cleavable linker, non-cleavable linker, and linker less.
The cleavable linker segment is likely to dominate the market during the forecast period. The ability of cleavable linkers to remain stable in the bloodstream for an extended period and release cytotoxin from ADCs makes them the most broadly utilized technology for achieving an effective outcome from ADCs in cancer treatment. For instance, in 2020, the NMPA approved Seagen’s and Takeda’s Adcetris for treating relapsed Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma sALCL in China. Such factors are expected to drive the cleavable linker market segment during the forecast period.
The non-cleavable linker segment is the second-highest revenue-generating segment, due to the increased usage of Kadcyla, which contains a non-cleavable linker, which is employed in the synthesis of ADCs that concentrates on lysosomal degradation and prevents non-specific drug release, decreasing the overall cytotoxicity of the ADC to surrounding healthy cells. During the projection period, this is expected to drive the segment. Only FDA-approved ADCs, such as Kadcyla and Blenrep, currently use non-cleavable linkers to bind the antibody and cytotoxic chemical.
Antibody Drug Conjugates Market by Application
Based on application, the global antibody drug conjugates market has been segmented into blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumor, and others.
The breast cancer segment is likely to dominate the market during the forecast period due to the increased prevalence of breast cancer worldwide. This growth may increase demand for effective therapies, such as ADCs, enhancing the market. In the metastatic setting, HER2-positive breast cancer has a poor prognosis, with a median overall survival of 15 months following standard chemotherapy.
Antibody Drug Conjugates Market by Distribution Channel
Based on the distribution channel, the global antibody drug conjugates market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment is likely to dominate the market during the forecast period as hospitals have more operating capital to spend on cutting-edge medical technologies, and they have taken the initiative. As hospitals are usually multi-specialty centers, they have the necessary medical equipment to provide patients with comprehensive care.
Antibody Drug Conjugates Market by Region
Based on region, the global antibody drug conjugates market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East, and Africa.
North America is likely to dominate the market during the forecast period due to increased cancer incidence and technological advancements. The region is experiencing substantial growth due to technical improvements in regional countries, such as the United States, Canada, and Mexico. In terms of clinical information, North America is a relatively developed region, and the usage of ADCs is considered and accounts for the vast bulk of the established market.
Europe accounts for the market’s second-largest revenue share. One of the two currently marketed medications, Kadcyla, is manufactured by the European pharmaceutical behemoth Roche. Furthermore, Europe was the second region where the marketing of ADCs was permitted on a priority basis. More than 190 clinical trials are now underway in Europe and North America.
During the forecast period, the Asia Pacific antibody drug conjugates market is expected to register growth at the fastest revenue CAGR. The approval of additional ADCs in the region has contributed to the region’s growth. For instance, Astellas’ enfortumab vedotin was awarded priority review by Japan’s MHLW in May 2021 for the treatment of metastatic or locally advanced urothelial carcinoma.
Antibody Drug Conjugates Market Competitive Landscape
Regulatory approvals are propelling the market. Sutro Biopharma Inc., for instance, acquired Fast Track designation from the US FDA for STRO-002 in September 2021. It is a folate receptor alpha (FolR)-targeting ADC authorized for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients who have received 1-3 prior lines of systemic therapy. Increasing company collaborations to develop ADCs may drive the market further in the future. For instance, Adcentrx Therapeutics and AvantGen announced a three-year, multi-target collaboration in February 2022 to find antibodies that will be turned into innovative ADC treatment candidates.
The prominent market players in the global antibody drug conjugates market include:
Antibody Drug Conjugates Market Strategic Developments
The antibody drug conjugates market is expected to register a revenue CAGR of 16.5% during the forecast period.
North America is the key revenue growth region in the global antibody drug conjugates market.
The rising geriatric population and growing R&D activities for developing novel therapeutics are the prime factors driving the market revenue growth.
The breast cancer segment leads the global antibody drug conjugates market by application.
Some prominent players in the global antibody drug conjugates market include Seagen Inc., ImmunoGen Inc., Pfizer Inc., Mersana Therapeutics Inc., and F. Hoffmann-La Roche Ltd.
*Insights on financial performance are subject to the availability of information in the public domain